Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands	Total	IPO	At The Market Offering	Convertible Preferred Stock	Common Stock	Common Stock IPO	Common Stock At The Market Offering	Additional Paid-in Capital	Additional Paid-in Capital IPO	Additional Paid-in Capital At The Market Offering	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2019	$ (142,542)				$ 1			$ 1,558			$ 26	$ (144,127)
Beginning balance (in shares) at Dec. 31, 2019				106,890
Beginning balance at Dec. 31, 2019				$ 417,359
Beginning balance (in shares) at Dec. 31, 2019					10,003
Issuance of Series B convertible preferred stock, net of $33 in issuance costs				$ 435,538
Issuance of convertible preferred stock, net of issuance costs, (in shares)				27,223
Issuance of common stock in connection with license agreements	680							680
'Issuance of common stock in connection with license agreement (in shares)					100
Vesting of restricted stock	1				$ 1
Vesting of restricted stock (in shares)					5,964
Stock-based compensation	5,829							5,829
Exercise of stock options	149							149
Exercise of stock options (in shares)					103
Unrealized gain (loss) on marketable securities, net	4										4
Net loss	(285,305)											(285,305)
Ending balance at Dec. 31, 2020	(421,184)				$ 2			8,216			30	(429,432)
Ending balance (in shares) at Dec. 31, 2020				134,113
Ending balance at Dec. 31, 2020				$ 852,897
Ending balance (in shares) at Dec. 31, 2020					16,170
Conversion of convertible preferred stock into common stock upon initial public offering	852,897				$ 13			852,884
Conversion of convertible preferred stock into common stock, upon initial public offering (in shares)				(134,113)
Conversion of convertible preferred stock into common stock, upon initial public offering (in shares)					134,113
Issuance of common stock, net of offering costs		$ 626,405				$ 3			$ 626,402
Issuance of common stock, net of offering costs (in shares)						27,025
Vesting of restricted stock (in shares)					5,916
Stock-based compensation	22,362							22,362
Exercise of stock options	3,167							3,167
Exercise of stock options (in shares)					1,586
Issuance of common stock related to employee stock purchase plan	2,179							2,179
Issuance of common stock related to employee stock purchase plan, Shares					119
Unrealized gain (loss) on marketable securities, net	(1,396)										(1,396)
Net loss	(355,928)											(355,928)
Ending balance at Dec. 31, 2021	$ 728,502				$ 18			1,515,210			(1,366)	(785,360)
Ending balance (in shares) at Dec. 31, 2021	184,929				184,929
Issuance of common stock, net of offering costs			$ 601							$ 601
Issuance of common stock, net of offering costs (in shares)							149
Vesting of restricted stock	$ 1				$ 1
Vesting of restricted stock (in shares)					4,395
Stock-based compensation	38,337							38,337
Exercise of stock options	$ 2,253							2,253
Exercise of stock options (in shares)	1,062				1,062
Issuance of common stock related to employee stock purchase plan	$ 2,058							2,058
Issuance of common stock related to employee stock purchase plan, Shares					487
Unrealized gain (loss) on marketable securities, net	(2,961)										(2,961)
Net loss	(269,476)											(269,476)
Ending balance at Dec. 31, 2022	$ 499,315				$ 19			$ 1,558,459			$ (4,327)	$ (1,054,836)
Ending balance (in shares) at Dec. 31, 2022	191,022				191,022